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Abstract
Although individually uncommon, rare diseases (RDs) collectively affect 6–8% of the population. The unmet need of the
rare disease community was recognized by the European Commission which in 2012 funded three flagship projects, RD-
Connect, NeurOmics, and EURenOmics, to help move the field forward with the ambition of advancing -omics research and
data sharing at their core in line with the goals of IRDiRC (International Rare Disease Research Consortium). NeurOmics
and EURenOmics generate -omics data and improve diagnosis and therapy in rare renal and neurological diseases, with RD-
Connect developing an infrastructure to facilitate the sharing, systematic integration and analysis of these data. Here, we
summarize the achievements of these three projects, their impact on the RD community and their vision for the future. We
also report from the Joint Outreach Day organized by the three projects on the 3rd of May 2017 in Berlin. The workshop
stimulated an open, multi-stakeholder discussion on the challenges of the rare diseases, and highlighted the cross-project
cooperation and the common goal: the use of innovative genomic technologies in rare disease research.
Introduction
Although individually uncommon, rare diseases (RDs)
collectively affect 6–8% of the population (ca. 30 million
people in the European Union) [1, 2]. Medical interventions
for RDs constitute a major part of healthcare spending [3].
Their rarity and diversity pose specific challenges for
healthcare provision and research, and for the development
and marketing of treatments. The unmet need of the rare
disease community was recognized by the European
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Commission, who in 2012 funded three flagship projects,
RD-Connect, NeurOmics and EURenOmics, to help move
the field forward with the ideas of harmonization and data
sharing at their core.
Genomics and other emerging omics technologies create
potential for gene-based treatments and personalized med-
icine, which are particularly important for RDs, since 80%
of RDs are genetic [2]. The capacity for genome and exome
sequencing is growing rapidly and the limiting factor is now
the ability to share and analyse these vast quantities of data
rather than generate them. Despite the advances in com-
puting technology, the processing and analysis of huge
amounts of omics data remains challenging and requires
new and innovative bioinformatics solutions and combined
analysis of genetic and clinical data.
Harmonization and data sharing across research centers
and across diseases is essential to advance knowledge,
particularly for RDs, where patients are scarce and geo-
graphically disparate. Transnational and transdisease efforts
are thus essential to make optimal use of resources. Patient
registries, biobanks and bioinformatics analysis methods are
the key infrastructure tools required for omics research.
Hundreds of RD biobanks and patient registries already
exist in Europe alone, and collaborative initiatives in spe-
cific disease groups have advanced the harmonization of
these infrastructures several areas.
A continued bottleneck for cutting-edge RD-research, is
that at present efforts of individual researchers continue to
multiply while remaining largely “siloed”, with almost no
information exchange. Genetic information, biomaterial
availability, detailed clinical information (deep phenotyp-
ing) and research/trial datasets are hardly ever system-
atically connected beyond an individual research lab, and
are rarely made accessible for reuse.
The International Rare Diseases Research Consortium
(IRDiRC), launched in 2011, unites researchers and orga-
nizations investing in RD-research in two common goals:
delivering 200 new therapies for RDs and the means to
diagnose most RDs by the year 2020. The first goal has
been achieved already in early 2017 [4]. However, some of
these therapies target the same disease, while for the vast
majority RD patients no treatment is available [4, 5]. Rarity
remains the biggest bottleneck in therapy development for
RDs.
Because of the large collective proportion of the popu-
lation affected, and the significant burden they place on
healthcare systems, RDs are a priority for research funded
by the European Commission. Between 2007 and 2017, the
EC funded €900 million in collaborative research projects
on RDs including NeurOmics, EURenOmics, and RD-
Connect [6]. NeurOmics and EURenOmics discovered
jointly over 120 new disease genes, while RD-connect
developed an infrastructure to facilitate the sharing and
analysis of this data, which holds now data from almost
3000 individuals. This collaborative approach represents a
new frontier of RD-research, diagnosis and therapy devel-
opment. In this review, we present the accomplishments of
these three projects, their role in the RD research and
outlooks.
RD-Connect
RD-Connect (www.rd-connect.eu) is a global research and
infrastructure resource for RDs. Set up to overcome the
siloing, fragmentation and inaccessibility of datasets from
different rare disease projects, RD-Connect links omics data
with phenotypic data and information in registries and
biobanks at both an individual-patient and whole-cohort
level. This enables researchers to analyse their own data and
compare them with others to gain a complete view of their
disease and patient population of interest. Data shared
through RD-Connect are accessible beyond the usual
institutional and national boundaries and researchers
worldwide can benefit from the opportunity to work with
others in the RD field, relate human phenotypes to a par-
ticular gene or pathway of interest, pool data to create larger
cohorts, find confirmatory cases, and access samples for
further study. This has been made possible through the
strong collaboration with NeurOmics and EURenOmics
(Fig. 1).
The integrated genome-phenome analysis platform
developed by RD-Connect brings together anonymised
omics and clinical data with tools and services to analyse
this data online. The central portal provides access to the
genomics analysis interface, the PhenoTips database [7]
storing human phenotype ontology (HPO)-coded pheno-
typic profiles for individual cases [8]. It also provides a
directory of biobanks and patient registries and a biosample
catalogue that allows drill-down to details of individual
samples hosted in participating biobanks.
Genomics analysis interface
To let researchers reach the same results regardless of the
sequencing provider used, RD-Connect re-processes raw
data through a single pipeline to standardize variant calling
and annotation. RD-Connect’s mechanism for sharing and
analysis of RD genomic data begins with submission of the
raw .bam or .fastq files, which is essential in order to allow
data from multiple sequencing providers to be processed
through the standard pipeline and to ensure comparability.
The raw data are stored for long-term access at the Eur-
opean Genome-Phenome Archive (EGA) [9], a secure,
controlled-access repository, while the processed data are
made accessible online for real-time analysis in the RD-
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Connect genomics analysis interface. This workflow not
only allows the researchers themselves to analyse their own
cases but also ensures that the samples and data are
accessible to others, thus maximizing the added value of the
project for future research (Fig. 2).
Thanks to the collaboration with NeurOmics and EURe-
nOmics, the Genome-Phenome Analysis Platform (https://
platform.rd-connect.eu) is a rich resource containing whole
exomes and genomes of a large number of individuals with
rare neuromuscular (NMD) or neurodegenerative (NDD)
(NeurOmics) and rare kidney disease (EURenOmics), but it
is also growing rapidly for other RD groups, such as mito-
chondrial, neurogenetic and immunological disorders. In
December 2017, the Platform contained exomes and gen-
omes of almost 3000 cases, uploaded by numerous research
projects, and the number is rapidly increasing.
RD-Connect believes that empowering disease experts to
do their own analysis online will speed up diagnosis and
gene discovery as well as give incentives for data sharing.
This has proven a success as RD-Connect has already
played a key role in the discovery of almost 20 published
novel RD-genes and phenotypes. The Genome-Phenome
Analysis Platform is a user-friendly tool for diagnosis and
gene discovery, accessible to all, even those without
experience in bioinformatics. A straightforward, secure
registration process allows researchers to access the Plat-
form to analyse and query their own data as well as data
submitted by others. The data are accessible to authorized
users following a predefined 6-month embargo period that
gives researchers exclusive access to their own data before
they are shared more widely.
A researcher can select one or multiple individuals (e.g.,
trios or other family relationships) to study and then filter
and refine the results by mode of inheritance, population
frequencies, in silico pathogenicity prediction tools, gene
lists and ClinVar, HPO and OMIM codes. In addition, the
integrated Exomiser tool extracts HPO terms describing the
symptoms of the affected patients (from PhenoTips) and
selects genes that match them.
The integrated matchmaker exchange system [10, 11]
allows individuals with a variant in the gene of interest that
may have been to comparing their symptoms and confirm a
gene discovery. The Global Alliance for Genomics and
Health’s “beacon” application programming interface (http://
ga4gh.org/#/beacon) has been implemented, which enables
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Fig. 1 Collaboration between NeurOmics, EURenOmics and RD-
Connect. Two research projects, NeurOmics and EURenOmics, gen-
erate large amounts of rare disease (RD) data (box “Research data and
samples”) using a number of methods and approaches (box “Research
methods”). These yield new therapies and improved diagnosis for RD
patients. The omics and deep clinical phenotyping data are uploaded to
the RD-Connect Genome-Phenome Analysis Platform (box “Infra-
structure for sharing and analysis”), which allows their analysis leading
and gene discovery. Researchers from the two projects also provide
user feedback helpful in the Platform development. Information about
patient registries and biobanks holding NeurOmics and EURenOmics
patient data and biosamples are entered in the RD-Connect Registry &
Biobank Finder, while detailed information about collected biosamples
is shared via the RD-Connect Sample Catalogue. Those data are linked
within the RD-Connect infrastructure are shared with the global RD
research community, which facilitates rare disease research, diagnosis
and therapy development and thus contributes to the IRDiRC goals. To
address ethical, legal, and social issues, all three projects work together
on developing appropriate best practices for international sharing of
patient data
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Fig. 2 Data flow within the RD-Connect infrastructure. Samples
donated by RD patients are deposited in biobanks, which allows their
usage for further research. Sample sequencing produces omics data,
which are uploaded to and processed in the RD-Connect Genome-
Phenome Analysis Platform and deposited in the European Genome-
Phenome Archive (EGA) for future reuse. In parallel, detailed patient
phenotypic records are also uploaded to the platform and linked to the
omics data. The platform allows clinicians and researchers to analyse
combined genomic and phenotypic data to diagnose patients and
discover novel disease genes and phenotypes
RD-Connect, NeurOmics and EURenOmics...
querying of the presence or absence of single variants in the
RD-Connect cohort.
The runs of homozygosity (RoH) feature allows identi-
fication of consanguineous cases even when not flagged as
such by the treating clinician. To focus gene discovery
search, RoH narrows the search down to only those geno-
mic regions that are homozygous in the patient.
In addition to the resources offered through the Genome-
Phenome Analysis Platform, RD-Connect partners have
developed a number of bioinformatics tools to assist
researchers in omics analysis and therapeutic target identi-
fication. These include variant analysis and annotation tools
such as UMD-Predictor (http://umd-predictor.eu/) [12, 13],
Human splicing finder (http://www.umd.be/HSF3/) [14],
VarAFT (http://varaft.eu/) as well as therapeutic prediction
tools and gene–drug interaction resources. The three tools
have already contributed to over 1000 genetic studies. The
genome–phenome analysis platform also contains the
ALamut® Functional Annotations (ALFA) (Interactive
Biosoftware, Rouen, France, http://www.interactive-
biosoftware.com/)—a gene regulation prediction software
tool designed to evaluate in silico potential effects of non-
coding DNA variations.
Biobanks and patient registries
RD-Connect activities in the patient registry arena focus on
enabling data linkage across resources and on the principle
of making registry data findable, accessible, interoperable
and reusable (FAIR) [15]. This approach is gaining sig-
nificant traction internationally through the European Open
Science Cloud (www.eoscpilot.eu) and NIH Commons
(https://commons.era.nih.gov/commons/). The rationale
behind its application in the patient registry context is to
allow computers to assist in analysis that otherwise is either
impossible due to incompatibilities between datasets, or
requires manual data aggregation and labor-intensive
interrogation of the data.
To maximize the potential of patient registries and bio-
banks, RD-Connect has developed two complementary
systems: the Registry & Biobank Finder (http://catalogue.
rd-connect.eu/) [16] providing information about existing
registries and biobanks worldwide, and the Sample Cata-
logue (https://samples.rd-connect.eu/) [17, 18] enabling
searchable access to biosample records at an individual
sample level. The RD-biobank network EuroBioBank [19]
is the de facto biobank network for RD-Connect.
Ethical, legal, and social issues and patient
involvement
Sharing sensitive data for research reuse raises many ethi-
cal, legal, and social issues (ELSI). To address them, RD-
Connect has developed ethical best practices that protect
patient privacy without hindering research. ELSI experts
within RD-Connect are engaged in establishing the ethical
framework under which RD-Connect can enable sharing of
sensitive human data in a secure and ethical fashion [20].
All researchers wishing to use the RD-Connect platform
sign the RD-Connect code of practice based on legal
requirements and ethical principles as well as patient and
scientific needs.
Input of patient representatives into RD-Connect, Neu-
rOmics, and EURenOmics activities is managed by
EURORDIS through the Patient Advisory Council (PAC;
http://rd-connect.eu/committee/pac/) and Patient and Ethics
Council (PEC; http://rd-connect.eu/committee/rd-pec/),
which have provided valuable guidance on the project’s
direction, particularly in ethically challenging areas relating
to data sharing where risk and benefit must be carefully
evaluated. PAC members engage with each of the RD-
Connect technical work packages, which not only enables
the technical experts to have direct input from the PAC, but
also strengthens the commitment and engagement of the
PAC members, supports capacity building, and improves
dissemination of the project’s outputs to the wider RD
patient community.
RD-Connect along with NeurOmics and EURenOmics
are embedded in European collaborative projects and work
with research infrastructures, such as BBMRI [21] and
Elixir (www.elixir-europe.org). The unique value of RD-
Connect is that is has built RD community by integrating
different stakeholders, such as scientists, clinicians, IT
experts, ethicists, lawyers, and patients, who otherwise
would have limited opportunities to work together. The
success of RD-Connect makes it the flagship project of the
European Commission.
NeurOmics
NeurOmics (www.rd-neuromics.eu) investigates several
rare neurodegenerative (NDD) and neuromuscular (NMD)
diseases. It aims to improve the lives of patients by iden-
tifying new disease-causing genes, establishing new and
standardized diagnosis tools, establishing biomarkers to
monitor disease progression and treatment efficiency, find-
ing new genetic modifiers of disease onset and course, and
developing novel therapeutic approaches (Fig. 1).
The project has undertaken whole exome (WES) and
whole genome sequencing (WGS) of 1105 samples,
patients and family members, which resulted in the identi-
fication of over 100 new disease genes (Table 1), of which
89 are already published mostly in high ranking journals
(Supplementary Table 2). For 43 genes, novel phenotypical
associations were established in 50 independent
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publications (Supplementary Table 3). This achievement
will greatly improve the diagnosis of rare neurodegenerative
and neuromuscular diseases and will increase understanding
of their pathogenesis.
To understand the relationship between genes and the
phenotype, NeurOmics researchers have entered data of
1550 patients into the PhenoTips system, which helps them
to describe the clinical features using the standardized HPO
terms. This allows matching patients with similar pheno-
types and share the data through the PhenomeCentral
database.
NeurOmics also combines -omics in animal models and
cutting-edge cellular models (human-induced pluripotent
stem cells) and uses mouse models in therapy development,
e.g., antisense oligonucleotide-mediated exon skipping [22,
23].
To improve and speed up the sequencing of patients,
NeurOmics has developed targeted NGS panels (Supple-
mentary Table 4), which allow quick analysis of selected
sets of all known genes associated with the disease of
interest. The panels have already been used for diagnosis of
over 700 patients. To monitor disease progression in
patients, NeurOmics is investigating disease biomarkers and
has developed profiling methods for metabolites and lipids
in plasma and cerebrospinal fluid based on ultra-high per-
formance liquid chromatography coupled high resolution
mass spectrometry (UPLC-HRMS) [24, 25].
The great success of NeurOmics is a result of not only
excellent science and best practice but also of strong col-
laboration and data sharing between partners from across
the project.
Case study 1: Data sharing helps to identify new genes
associated with rare diseases.
Two patients suffering from proximal muscle weakness
mainly in the lower limbs were analysed by two NeurOmics
research teams in Newcastle and London. The first case,
based in Newcastle, UK, was a man in his fifties, whose
symptoms had been slowly progressing since childhood.
The London case was a 4-year-old boy also presenting with
weakness of the neck and spine. In both cases, muscle
biopsy indicated congenital myopathy. Exome analysis
revealed that both patients carried disease-causing variants
in the gene SRPK3. Using a genome-phenome analysis
platform for data sharing, the research teams discovered that
they had patients with variants in the same gene and
exchanged information. This strongly supported SRPK3 as
a disease-causing gene in these patients and will now allow
personalized genetic counseling. Thanks to data sharing,
researchers identified SRPK3 as a congenital myopathy
gene, which will help other researchers worldwide to
diagnose similar patients in the future. [Töpf A et al. in
preparation]
EURenOmics
EURenOmics (www.eurenomics.eu) aims to improve the
lives of patients living with rare kidney diseases through
developing tools for more accurate diagnoses, prognosis
and developing new and better therapies this population
(Fig. 1).
EURenOmics performed WES in 315 families resulted in
the discovery of 11 new genomic rearrangements and 26
novel disease genes (Table 1), of which 20 have been
already published (Supplementary Table 5). The lower
number of gene discoveries than in NeurOmics is attributed
to lower genetic complexity of the kidney. In parallel,
EURenOmics established several novel cellular and animal
models, to study the biological mechanisms of rare kidney
diseases. To improve diagnosis, EURenOmics has
Table 1 Research outputs of NeurOmics and EURenOmics
NeurOmics
Samples analysed by WES/WGS 1105
Discovered disease genesa >100
Novel phenotypical associationsb 43
Diagnostic panelsc 8
Genes covered in the panels 1663
Samples analysed by diagnostic panels 3840
Diseases covered by biomarker analysis 3
Therapeutic trials/studies (HD, MD, SCA, 2x HSP) 5
EURenOmics
Families analysed by WES/WGS 315
Discovered disease genes and genomic rearrangements 37
Disease genesd 26
Genomic rearrangements 11
Diagnostic panelse 5
Genes covered in the panels 687
Samples analysed by diagnostic panels >4000
Diseases covered by biomarker analysis 5
Therapeutic trials/studies 3
The research outputs of the two projects include novel disease genes,
diagnostic panels, novel biomarkers, and therapeutic trials. Many of
the gene discoveries were done with the contribution from RD-
Connect
a For the full list of the published novel disease genes published, see
the Supplementary Table 2
b See Supplementary Table 3
c See Supplementary Table 4
d For the full list of the published novel disease genes, see the
Supplementary Table 5
e See Supplementary Table 6
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developed targeted NGS panels, covering 687 genes for rare
kidney diseases (Table 1). Validated panels have been used
in over 4000 cases and allowed diagnosis in 6–65% in
various diseases (unpublished information, Supplementary
Table 6).
Identification of the gene causing the patient’s disease is
crucial for developing the right treatment or applying an
already existing therapy for a different disease (see case
study 2).
Case study 2: Genetic diagnosis allows targeted therapies.
At the age of 6, a male patient was diagnosed with steroid-
resistant nephrotic syndrome (SRNS)—a disease that causes
abnormalities in kidney function and excess of protein in
the urine (proteinuria), which often leads to kidney failure.
Researchers in EURenOmics discovered that his symptoms
are caused by variants in the gene ADCK4, which impair the
biosynthesis of Coenzyme Q10 (CoQ10) and lead to a
kidney-specific mitochondrial dysfunction. Supplementa-
tion with oral CoQ10 reduces proteinuria. The same variant
was found in the patient’s sister, who also had proteinuria,
but showed no symptoms. CoQ10 supplementation has
been applied in both children to maintain the kidney
function in long-term.
To facilitate genetic diagnosis, the researchers have
developed NGS gene panels that allow doctors to quickly
check whether a sick child has variants in genes known to
be associated with certain kidney diseases. The screening of
a cohort of 1000 children with SRNS revealed that up to
10% of the patients who receive a genetic diagnosis are
affected by treatable hereditary defects of CoQ10 bio-
synthesis. Hence, a progressive kidney disease previously
considered untreatable has turned into an easily treatable
condition in at least some of the affected children, thanks to
progress in gene discovery and routine genetic diagnostics
[26].
The precise genetic diagnosis allowed for genetic counsel-
ing important for future family planning. The parents were
recommended in-vitro fertilization with preimplantation
diagnostics, which allowed them to get a healthy son.
The integration of patient databases and advances in gene
diagnostics have allowed the collection of detailed infor-
mation on the disease and patient symptoms (deep pheno-
typing) and genotype–phenotype association studies in the
largest cohorts of genetically classified patients with various
rare kidney diseases [27–36].
The consortium also increased the understanding of the
pathophysiological role of common variants and therapeutic
modification not only in kidneys but also in non-renal
systemic and organ-limited diseases, e.g. the role of tubu-
lopathy genes in hypertension, cardiovascular and stone
disease [37]. Thus, rare disease research contributes to
finding potential therapeutic targets also for common
diseases.
Apart from multi-omics, EURenOmics is also focusing
on epigenetic studies, which include leukocyte methylome,
miRNome profiling and CHiP-Seq analysis of key binding
sites to glomerular, tubular and developmental transcription
factors and epigenetic modifiers.
Case study 3: Developing best practice in consent.
The increasing use of new sequencing technologies and
increased international data sharing create new opportu-
nities for research and therapy development, but also
require adjustments of the existing informed consent
procedures. In RD-research, resources are scarce and it is
critical to facilitate the access and reuse of the existing
samples and data collections. In older collections, the
consent forms did not consider the new genome sequencing
technologies, the possibility of the return of incidental
finding (e.g. detecting a variant that highly increases the risk
of breast cancer) or research projects that involve
commercial partners, such as the pharmaceutical industry.
Without relevant consent, the samples and data cannot be
used or reused for research. It is therefore essential to make
efforts to re-contact patients, where required, to update their
consent. The three projects have developed guidelines on
the re-contacting procedure. Sometimes re-contacting is
impossible, for example because the patient is deceased or
where current contact details are not available. In such
cases, the researchers should apply for permission to use the
samples to institutional review boards/research ethics
committees (IRBs/RECs) [20].
For prospective studies, the three projects created tem-
plates of consent documents, which should include key core
elements and more broadly described research purposes
with ongoing updates for participants. Investigators need to
confirm that the consent for data sharing is in place when
entering patients into databases.
Both EURenOmics and NeurOmics continue close col-
laboration with RD-Connect, particularly in data sharing,
development of the HPO and standardization of ethical
aspects, such as consent procedures.
Conclusion
The establishment of the International Rare Diseases
Research Consortium (IRDiRC) in 2011 was a milestone
for the RD community. IRDiRC unites researchers and
institutions investing in RDs research worldwide to improve
patients’ lives by delivering new therapies for RDs and
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means to diagnose them. IRDiRC has developed “policies
and guidelines” and recommends specific resources to
enable and facilitate RD research [38, 39]. Since then, a
significant progress has been made in research and diag-
nosis and, with respect to therapies, even more was
achieved than initially expected. RD-Connect, NeurOmics
and EURenOmics have greatly contributed to those suc-
cesses by establishing new approaches in research, diag-
nosis and therapy development and an infrastructure that
makes allows implementing them. However, despite of the
great achievements of IRDiRC and contributing projects,
most patients still lack diagnosis and treatment, and the RD
community faces a number of challenges, which need to be
addressed in near future [4].
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